ClinicalTrials.gg
CompletedNCT07412288Updated Nov 2, 2026

First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants

A Phase 1 interventional study of KT-579 and Placebo in Healthy Participants, sponsored by Kymera Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Kymera Therapeutics, Inc. · Phase 1, Interventional, and Other

How we know

Updated Nov 2, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a first-in-human study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-579 in healthy male and female adult participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • Phase 1
  • IRF5
  • IRF5 degrader
  • targeted protein degrader
03

In context

Lead sponsor

Kymera Therapeutics, Inc. is the lead sponsor of 12 studies on the registry; 3 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a weight of at least 50 kg if male or 40 kg if female, and a (BMI) between 18.0 and 32.0 kg/m² (inclusive) at Screening.
  • Participants must be willing and able to read, understand, and sign an form (ICF) which includes compliance with requirements and restrictions listed in the ICF and in this protocol.
  • Participants must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • Participants who have a history of respiratory, gastrointestinal (GI), renal, hepatic, hematological, lymphatic, endocrinological, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, ophthalmological, or connective tissue diseases or disorders.
  • Participants who have a clinically relevant surgical history (e.g. surgery of the GI tract that could interfere with the PK of the trial medication) Note: prior appendectomy or cholecystectomy is not exclusionary.
  • Participants with a history of alcohol or substance abuse within the previous 2 years.
  • Participants who have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease.
  • Participants who test positive for alcohol and drugs of abuse at Screening and on admission to the CRU.
  • Participants who have acute GI symptoms at the time of Screening or on admission to the CRU (e.g. nausea, vomiting, diarrhea, heartburn).
  • Participants whose results from clinical laboratory safety tests are outside the local reference range at Screening and on admission to the CRU.
  • Participants who have previously received KT-579 in another cohort in this study.
  • Participants who have been dosed with any drug or device in a clinical study within 30 days or 5 half-lives (whichever is longer) of KT-579/placebo administration.
  • Male participants who do not agree to refrain from sperm donation from admission to the CRU to 90 days after the last dose of study drug.
  • Male participants (and their partners of ) and female participants who do not agree to the requirements as specified in the clinical protocol.
  • Female participants who are pregnant, lactating, or breast-feeding or plan to become pregnant (including ova donation) within 30 days of last study drug administration.
  • Female participants with a positive or undetermined pregnancy test at Screening and on admission to the CRU.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
96 participants (actual)

Study arms

  • Active comparator
    KT-579

    Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of KT-579.

    Drug: KT-579

  • Placebo comparator
    Placebo

    Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of matched placebo.

    Drug: Placebo

Interventions

  • DrugKT-579

    Oral drug

  • DrugPlacebo

    Oral drug

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)

  2. Incidence of serious adverse events

    Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)

Secondary outcomes

  1. Maximum concentration (Cmax): observed maximum concentrations derived from plasma concentration data

    Time frame: Day 1 (SAD); Day 1, Day 7, and Day 14 (MAD)

  2. Time to maximum concentration (Tmax): observed time to achieve maximum concentrations derived from plasma concentration data

    Time frame: Day 1 (SAD); Day 1, Day 7, and Day 14 (MAD)

  3. Area under the curve (AUC0-last): Area under the plasma concentration-time curve calculated using non-compartmental analysis from time zero to the last observed timepoint

    Time frame: Day 1 (SAD); Day 1, Day 7, and Day 14 (MAD)

  4. Area under the curve (AUC0-infinity): Area under the plasma concentration-time curve calculated using non-compartmental analysis from time zero to infinite time

    Time frame: Day 1 (SAD)

  5. Area under the curve (AUC0-tau): Area under the plasma concentration-time curve calculated using non-compartmental analysis from time zero to end of the dosing interval

    Time frame: Day 1, Day 7, and Day 14 (MAD)

  6. Terminal elimination half-life (t1/2): elimination half-life calculated using non-compartmental analysis

    Time frame: Day 1 (SAD) and Day 14 (MAD)

  7. Fraction excreted: Fraction of drug excreted unchanged in urine

    Time frame: Day 14 (MAD)

Other outcomes

  1. Change from baseline in IRF5 protein levels in whole blood and peripheral blood mononuclear cells (SAD)

    Time frame: Day 1

  2. Change from baseline in IRF5 protein levels in whole blood, peripheral blood mononuclear cells, and skin (MAD)

    Time frame: Day 1 to Day 14

07

Study locations

1 site
  • Celerion
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2026 to primary completion in Aug 2026, 5 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Dec 2026 → Aug 2026 and completion Dec 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Feb 17, 2026
StartActual
Feb 23, 2026
Primary completionActual
Aug 22, 2026was Dec 2026
CompletionActual
Aug 22, 2026was Dec 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 2, 2026
Primary completion
Dec 2026→Aug 22, 2026 (actual)
Nov 2, 2026
Study completion
Dec 2026→Aug 22, 2026 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Recruiting→Completed
    Primary completion Dec 2026→Aug 22, 2026 (now actual)
    Study completion Dec 2026→Aug 22, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07412288
Lead sponsor
Kymera Therapeutics, Inc.
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Feb 23, 2026
Primary completion
Aug 22, 2026
Completion
Aug 22, 2026
Last update
Nov 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion